Evidence map›Paper›PMID 39470195›Full record

ArticleAntimicrobial agents and chemotherapy2024

Multidrug tolerance conferred by loss-of-function mutations in anti-sigma factor RshA of

Wassihun Wedajo Aragaw, Tewodros T Gebresilase, Dereje A Negatu, Véronique Dartois, Thomas Dick

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wassihun Wedajo AragawCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.ORCID 0000-0002-4199-2224
Tewodros T GebresilaseArmauer Hansen Research Institute (AHRI), Addis Ababa, Ethiopia.
Dereje A NegatuCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
Véronique DartoisCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.ORCID 0000-0001-9470-5009
Thomas DickCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.ORCID 0000-0002-9604-9452

Funding

Discovery of novel lead-target pairs and identification of all-oral bactericidal drug regimens for Mycobacterium abscessus lung diseaseR01AI132374 · NIAID · RBHS-NEW JERSEY MEDICAL SCHOOL · PI Thomas Dick · 2018 to 2026
$7.0M
Shorter and more effective oral regimens for M. abscessus pulmonary diseaseR01AI184502 · NIAID · HACKENSACK UNIVERSITY MEDICAL CENTER · PI Thomas Dick · 2025 to 2026
$1.8M
NIAID NIH HHS R01 AI132374NIAID NIH HHS R01 AI184502
6 · The paper itself

Abstract

Low-level drug resistance in noncanonical pathways can constitute steppingstones toward acquisition of high-level on-target resistance mutations in the clinic. To capture these intermediate steps in

Indexed as

Anti-Bacterial AgentsBacterial ProteinsMicrobial Sensitivity TestsMoxifloxacinMycobacterium abscessusSigma FactorDrug Resistance, Multiple, BacterialLoss of Function MutationOxidative StressAnti-Bacterial AgentsBacterial ProteinsMoxifloxacinSigH protein, bacteriaSigma Factordrug resistancefluoroquinoloneMycobacterium abscessusSigHstress responsetolerance

Identifiers

PMID39470195
PMCPMC11619451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.